General Information of the Drug (ID: M6APDG03587)
Name
ISIS 138616
Status
Investigative
TTD Drug ID
D0DH8B
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Helicase-moi messenger RNA (DICER1 mRNA)
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138616. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138616 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [1], [2]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138616. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 138616 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [1], [2]
YTH domain-containing protein 1 (YTHDC1)
In total 1 mechanisms lead to this potential drug response
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138616. The YTH domain-containing protein 1 (YTHDC1) has potential in affecting the response of ISIS 138616 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [1], [2]
References
Ref 1 The m(6)A-methylase complex recruits TREX and regulates mRNA export. Sci Rep. 2018 Sep 14;8(1):13827. doi: 10.1038/s41598-018-32310-8.
Ref 2 US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.